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Abstract
Deadenylases are best known for degrading the poly(A) tail during mRNA decay. The deadenylase 
family has expanded throughout evolution and, in mammals, consists of 12 Mg2+-dependent 3’ 
end ribonucleases with mostly unknown substrate specificity1. Pontocerebellar hypoplasia type 7 
(PCH7) is a unique recessive syndrome characterized by neurodegeneration with ambiguous 
genitalia2 (MIM%614969). We studied 12 human families with PCH7, uncovering biallelic, loss 
of function mutations in TOE1 (NC_000001.11), which encodes an unconventional 
deadenylase3,4. Toe1-morphant zebrafish displayed mid- and hind-brain degeneration, modeling 
PCH-like structural defects in vivo. Surprisingly, we found TOE1 associated with incompletely 
processed small nuclear (sn)RNAs of the spliceosome, which is responsible for pre-mRNA 
splicing. These pre-snRNAs contained 3’ genome-encoded tails often followed by post-
transcriptionally added adenosines. Human cells with reduced levels of TOE1 accumulated 3’ end-
extended pre-snRNAs, and immuno-isolated TOE1 complex was sufficient for 3’ end maturation 
of snRNAs. Our findings reveal the cause of a neurodegenerative syndrome linked to snRNA 
maturation and uncover a key factor involved in processing of snRNA 3’ ends.
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
**Addressed correspondence to: J.L-A. jlykkeandersen@ucsd.edu, F.B. f.baas@amc.uva.nl and J.G.G. jogleeson@rockefeller.edu.
*These authors contributed equally.
Author contributions
A.E.S., S.J.M., N.A., A.G.-G., L.D.H., and A.G. performed fibroblast, iPSC, NPC and knockout mouse experiments. R.M.L. 
generated stable cell lines and performed all snRNA/P experiments. V.R.E., N.A., E.S., D.M., R.M., A.W., A.E.S., E.D., and R.O.R. 
analyzed clinical and exome results. S.L.G., A.E.S., Z.S., B.R., A.G.-G., I.M.-V., and L.D.H. generated zebrafish data, and N.C. and 
D.T. provided resources for zebrafish experimentation. M.S.Z., N.F., W.B.D., L.S., S.M.B., E.M.V., J.H.D., L.D.M., H.K., U.A., 
M.L.F., L.W., D.C., C.F., M.K., K.A.A., D.M., N.M., A.O.Ç, K.B., H.P., M.-C.N., H.S., M.S., K.O., and K.M. conceived of genetic 
investigation. S.B.G., M.G. supported exome sequencing. E.L.V.N., S.S., T.L.S., and G.W.Y. supported RNA sequencing and 
computational analysis. E.J.B. performed mass spectrometry. R.L.M, A.E.S., J.L.-A. and J.G.G. wrote the manuscript. R.L.M., A.E.S., 
V.R.E., Z.S., N.C., D.T, G.W.Y., F.B., J.L.-A., and J.G.G. edited the manuscript. J.L.-A., F.B. and J.G.G. directed the project.
Competing financial interests
The authors declare no competing financial interests.
Accession codes. The exome sequencing data for all individuals consented for public release of data in this study have been deposited 
to the database of Genotypes and Phenotypes (dbGaP) under accession phs000288.v1.p1. RNA sequencing has been deposited into 
Gene Expression Omnibus (GEO) under accession GSE71536.
Online Resources.
NHLBI Exome Sequencing Project (ESP) http://evs.gs.washington.edu/EVS/
SeattleSeq http://snp.gs.washington.edu/SeattleSeqAnnotation137/
OMIM http://www.omim.org/
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2/http://genetics.bwh.harvard.edu/pph2/
Greater Middle Eastern Variome http://igm.ucsd.edu/gme/
HHS Public Access
Author manuscript
Nat Genet. Author manuscript; available in PMC 2017 July 16.
Published in final edited form as:
Nat Genet. 2017 March ; 49(3): 457–464. doi:10.1038/ng.3762.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
TOE1; CAF1Z; Pontocerebellar hypoplasia; snRNP; snRNA; deadenylation
Pontocerebellar neurodegeneration has its onset so early as to overlap with 
neurodevelopment and is thus alternatively referred to as pontocerebellar hypoplasia 
(PCH)5. PCH7 is characterized by neurological deterioration, atrophy/hypoplasia of the pons 
and cerebellum, muscular hypotonia, and breathing abnormalities, combined with 
hypogonadism2. This combination of rare conditions suggested a unique syndromic 
association due to a single gene mutation, but no locus or causative gene has been identified 
to date. We recruited 12 families meeting criteria for PCH7 including the index family that 
defined the condition (Fig. 1a) and confirmed that clinical features matched those published 
(Supplementary Table 1), including reduced pons/cerebellum parenchyma (Fig. 1b) 
ventriculomegaly, thin corpus callosum, and variable hypogonadism, ranging from absent 
gonads to ovarian and uterine remnants or atrophic and undescended testes (Supplementary 
Fig. 1a, b). All patients/families were enrolled in Institutional Review Board-approved 
protocols at referral institutions and provided consent for study. We performed whole exome 
sequencing in the proband and parents from Egyptian families 1275 and 1603. Aligning the 
genomic variants uncovered a p.E220K homozygous mutation in TOE1 within a shared 
haplotype of 500 kb (Fig. 2a, Supplementary Fig. 2a, b), indicative of shared ancestry. All 10 
additional families enrolled subsequently proved positive for biallelic mutations in TOE1 
(Fig. 2a, Supplementary Table 2). The variants were all predicted to impair expression of full 
length TOE1 or affect protein function6 by altering well-conserved amino acids (Fig. 2b) 
and were not observed in our 4,000 in-house ethnically-matched exome database. We 
confirmed that each variant segregated according to a recessive mode of inheritance in all 
genetically informative members of each family, suggesting TOE1 biallelic mutations 
underlie PCH7.
To test if TOE1 missense mutations were likely to interfere with protein function, we 
modeled them on the structure of the paralogous protein CNOT7 (Q9UIV1) (Supplementary 
Fig. 3a). Most variants were on surface residues, rather than within the RNA-binding cleft, 
suggesting they are not likely to directly affect deadenylase activity (Fig. 2c). We next 
established primary fibroblast cultures from patients carrying the homozygous p.E220K, 
p.F148Y and p.A103T mutations, as well as unaffected relatives (Family 1603, 4127 and 
4128, respectively). Patient fibroblasts had reduced levels of TOE1 protein by Western blot 
(Fig. 2d, Supplementary Fig. 3b). Additionally, neural progenitor cell (NPC) lines derived 
from an affected patient of Family 1603 showed less TOE1 protein than an unaffected 
relative and control NPCs (Fig. 2e, Supplementary Fig. 3b, c). Together, these results 
indicate TOE1 amino acid substitutions negatively affect protein accumulation.
To verify TOE1 mutations affect protein levels, we generated single-site integration T-
REx-293 cell lines for tetracycline-regulated expression of siRNA-resistant wild type human 
TOE1 (WT) and p.E220K, p.F148Y, p.V173G, and p.A103T variants. When depleted of 
endogenous TOE1 and induced with a concentration of tetracycline that promoted 
accumulation of TOE1-WT to near endogenous levels, we observed reduced levels of mutant 
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compared with TOE1-WT, despite similar mRNA levels (Supplementary Fig. 3d, e). By 
contrast, a previously characterized catalytically inactive mutant of TOE1 (DE) accumulated 
to similar levels as WT (Supplementary Fig. 3e)4. These results are consistent with our 
findings from patient cell lines, and indicate the patient mutations are deleterious by 
reducing TOE1 levels.
Since Toe1 is expressed broadly in human and mouse tissue (Supplementary Fig. 4a, b), we 
generated Toe1 mutant mice to test for defects in vivo. Embryos with homozygous Toe1 
frameshift mutations showed uniform lethality prior to embryonic day (e) 11.5 
(Supplementary Fig. 4c), demonstrating Toe1 is required for mouse development. Because 
the patient mutations allow for partial expression of TOE1 protein, we next turned to 
morpholino (MO) knockdown in zebrafish, where dosage could be regulated, to create a 
PCH7 disease model (Supplementary Fig. 5a). Knockdown of the single toe1 orthologue 
(NM_001256682.1) led to reproducible microcephaly, small eye, and curly tail phenotype in 
90% of embryos by 48 hours post fertilization (hpf), which was rescued by co-injection of 
human TOE1 mRNA but not the catalytically inactive DE mutant- or patient mutation-
encoding mRNAs (Fig. 3a, Supplementary Fig. 6a). To visualize neurons, we performed 
whole mount immunofluorescence for the neuronal marker, HuC. Like patients, toe1 MO 
injected fish showed structural defects of the developing midbrain, cerebellum and hindbrain 
(Fig. 3b). This phenotype was largely restored by co-injection of WT zebrafish or human 
TOE1, but not mutant mRNAs (Fig. 3b, Supplementary Fig. 5b, 6b). To determine if 
neuronal loss in the toe1 MO injected zebrafish was due to cell death, we performed cleaved 
caspase-3 (Casp3) staining at 24 hpf. While zebrafish injected with Control MO showed few 
Casp3-positive cells, toe1 MO-injected zebrafish showed a dramatic apoptotic response, 
consistent with neurodegeneration (Supplementary Fig. 5c). We conclude that reduced 
expression of TOE1 leads to neurodegeneration and PCH-like structural brain defects in 
vivo.
TOE1 was originally identified as a growth suppressor and direct target gene of Erg1, an 
immediate early transcription factor3. Alternatively called CAF1z due to homology with 
CAF1 deadenylases, we reported TOE1 as a 3’ to 5’ exonuclease with preference for 
adenosines in vitro4. Unlike characterized mRNA deadenylases, TOE1 concentrated in 
nuclear Cajal Bodies (CBs)4, which are rich in enzymes that process RNAs not known to 
have poly(A) tails, suggesting novel substrates. More recently, TOE1 was shown to associate 
with spliceosomal proteins7,8, which are known to localize to CBs, and TOE1 depletion 
caused defective splicing of a pre-mRNA reporter7. To validate TOE1 association with the 
spliceosome, we performed TOE1 knockdown followed by expression at near endogenous 
levels of FLAG-tagged TOE1-WT or -DE mutant in T-REx-293 cells, followed by 
immunoprecipitation (IP). As assessed by Northern blotting (Fig. 4a) and tandem mass 
spectrometry (MS) (Supplementary Fig. 7, Supplementary Table 3), TOE1 assembled with 
snRNAs and, with near complete overlap to previously reported IP-MS results7, with 
spliceosomal proteins. The CCR4-like protein Angel2/Ccr4d, which we previously reported 
in complex with TOE14 was not detected in our IP-MS, possibly due to low cellular 
abundance9.
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Inspection of Northern blots for TOE1-DE-associated snRNAs revealed slower migrating 
U1, U2, and U5 snRNA species (Fig. 4a, asterisks). Processing of Pol-II transcribed 
snRNAs, U1, U2, U4 and U5, initiates with co-transcriptional cleavage by the Integrator 
complex downstream of the mature 3’ end10, but the mechanism mediating removal of the 3’ 
tail to produce a mature length snRNA is unknown11,12. To characterize the slower 
migrating snRNAs, we performed 3’ end sequencing of TOE1-associated snRNAs and found 
TOE1 bound Pol-II transcribed snRNAs that were incompletely processed at the 3’ end (Fig. 
4b,c, Supplementary Fig. 8 - RIP), suggesting TOE1 may mediate snRNA 3’ tail processing.
TOE1-associated pre-snRNA 3’ tail sequences consisted of both genome-encoded and post-
transcriptionally added nucleotides, henceforth referred to as templated and untemplated 
tails, respectively (Figs. 4b, c, Supplementary Fig. 9a). The untemplated snRNA tails, which 
were previously observed by 3’ end sequencing of non-coding RNA13, were found almost 
exclusively on snRNAs that were either longer or shorter than annotated mature length and 
consisted primarily of uridines and adenosines, with TOE1-DE-associated snRNAs 
predominantly enriched for untemplated 3’ adenosines (Supplementary Fig. 9a, b). 
Interestingly, 3’ maturation of U2 snRNA finishes with the addition of an untemplated 3’ 
adenosine14, but this modification was entirely absent from TOE1-associated U2 snRNAs 
(Supplementary Fig. 9b). Taken together, these observations suggest that TOE1 associates 
specifically with pre-snRNAs that are not fully processed at the 3’ end, and often, have 
acquired untemplated tails.
snRNAs associated with TOE1-DE contained longer tails than those associated with TOE1-
WT, suggesting that TOE1 may catalytically process these tails. Consistent with this, 3’ end 
sequencing of the total snRNA pool revealed an increased fraction of 3’ end extended 
snRNAs upon depletion of TOE1 (Fig. 4b, Supplementary Fig. 8). Importantly, 
complementation with exogenous TOE1-WT rescued the snRNA 3’ end defect, while 
TOE1-DE failed to rescue (Fig. 4b, Supplementary Fig. 8). There was little to no 
accumulation of 3’ tails for the C/D box U3 or H/ACA box SNORA63 small nucleolar 
(sno)RNAs, 5.8S ribosomal (r)RNA, transfer (t)RNAs, or U6 snRNA (Supplementary Fig. 8, 
10), which like Pol-II transcribed snRNAs are processed from 3’ extended precursor 
RNAs15–18. These results support a catalytic role for TOE1 as a 3’ to 5’ exonuclease with 
specificity for snRNA processing.
TOE1 could promote either maturation or degradation of pre-snRNAs. To discriminate 
between these possibilities we tested the activity of immuno-isolated TOE1 on co-purifying 
pre-snRNPs in vitro. Northern blot analyses revealed Mg2+- and active site-dependent 
shortening of U1, U2, and U5 pre-snRNAs by TOE1 with no overall loss of snRNA levels 
(Fig. 5a), suggesting a function in maturation rather than degradation. 3’ end sequencing 
confirmed in vitro processing of U1, U2 and U5 by TOE1 halted at, or before, the mature 3’ 
end (Fig. 5b, Supplementary Fig. 11a) including at an alternative U5 3’ end also present in 
total cellular snRNA (Supplementary Fig. 8b). Consistent with a function in maturation 
rather than degradation, TOE1 depletion did not affect levels of unstable endogenous U1 
snRNA variants (Supplementary Fig. 11b)19, nor did it affect the levels or 3’ processing of 
unstable U1 snRNAs mutated in the Sm binding site (Supplementary Fig. 11c, d)20, 
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suggesting that the latter are targeted for degradation prior to 3’ processing by TOE1. We 
conclude that TOE1 acts in snRNA 3’ end maturation (Fig. 5c).
To determine whether TOE1 patient mutations affect snRNA processing, we performed 
snRNA 3’ end sequencing from the patient-derived cell lines. This revealed an increased 
fraction of U1 and U2 snRNAs, and to a less extent, U5 snRNA, containing tails in patient 
fibroblasts compared to unaffected relatives, which were indistinguishable from the control 
(Fig. 6a, Supplementary Fig. 12a, b). Similarly, patient-derived NPC lines showed 
enrichment for snRNA extensions (Fig. 6b, Supplementary Fig. 12a, b). We conclude that 
PCH7 patient cells accumulate incompletely processed snRNAs.
Here we show patients with PCH7 harbor biallelic, damaging mutations in TOE1, resulting 
in accumulation of incompletely processed snRNAs. The involvement of TOE1 in snRNA 
maturation was surprising given the homology with CAF1 mRNA deadenylases and the 
preference of TOE1 for poly(A) RNA in vitro4, but could provide a mechanistic explanation 
for the observed defect in pre-mRNA splicing upon TOE1 depletion7. The enrichment of 
snRNAs with untemplated 3’ adenosines associated with catalytically inactive TOE1 
suggests 3’ adenylation as a mechanism to recruit TOE1 to pre-snRNAs (Fig. 5c). The 
abundance of Sm subunits in the TOE1 IP-MS analysis (Supplementary Fig. 7, 
Supplementary Table 3) and the absence of processing of U1 snRNA mutated in the Sm 
binding site (Supplementary Fig. 11d) suggest the Sm-complex as another component 
important for TOE1 recruitment. PARN, which has been linked to familial pulmonary 
fibrosis, and PARN-like DEDD deadenylases were recently found to promote 3’ processing 
of snoRNAs and piRNAs, respectively15,21,22, and like snRNAs, RNA targets had templated 
and untemplated tails upon depletion of PARN15. Thus, adaptation of deadenylases to 
function in 3’ processing of non-coding RNAs in conjunction with poly(A) polymerases 
might be a general principle in RNA metabolism.
Our results suggest that perturbations in snRNA pools may contribute to PCH7 patient 
manifestations, although other currently unknown functions of TOE1 cannot be ruled out as 
causal to the disease. A defining feature of pontocerebellar degeneration is loss of motor 
neurons, akin to spinal muscular atrophy (SMA). The SMA disease gene, Survival of Motor 
Neuron 1, encodes a well-established snRNP assembly factor23,24, and together with our 
results suggest that maintaining proper snRNP biogenesis is important for neuronal survival. 
EXOCS3, encoding a core component of the 3’ RNA exonuclease exosome complex is 
mutated in PCH type 125, suggesting that there may be shared RNA targets for TOE1 and 
the exosome, perhaps snRNAs. Consistent with the idea that snRNAs are important for 
neuronal survival, a recent study identified recessive cerebellar degeneration resulting from a 
U2 snRNA mutation in mouse26. We and others recently described mutations in PCH 
patients in genes involved in protein synthesis, including CLP1 and other tRNA Splicing 
Endonuclease (TSEN) complex components leading to misprocessing of pre-tRNAs in 
patient cells27–30. While we found no defect in tRNA 3’ end processing in TOE1 mutant 
cells (Supplementary Fig. 10), CLP1 has also been implicated in snRNA 3’ end 
processing31, suggesting a possible link between TOE1 and CLP1 mutations in PCH. Our 
data along with other recent studies26,32 suggest defects in processing of small non-coding 
RNAs as a common cause of severe early onset neurodegenerative conditions.
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ONLINE METHODS
Patient recruitment
Patients were enrolled and sampled according to standard local practice in approved human 
subjects protocols at the University of California, The Rockefeller University and The 
Academic Medical Center (AMC) in Amsterdam for blood, saliva and skin biopsy sampling.
Sequencing
Blood was acquired from informed, consenting individuals according to institutional 
guidelines, and DNA extracted using established protocols. Exome sequencing was 
performed on both the parents and affected member(s) from each family as previously 
described34. All variants were prioritized by allele frequency, conservation, and predicted 
effect on protein function, and were tested by Sanger sequencing for segregation with 
disease. Sequence data were analyzed with Sequencer 4.9 (Gene Codes).
Genetic mapping
Chromosomal ideogram plot were generated using the Bioconductor package 
quantsmooth35. Red: homozygous regions that segregate between affected and unaffected 
family members.
Fibroblasts culture, iPSC, NPC generation
Fibroblasts were generated from unaffected and affected dermal biopsies explants. iPSCs, 
neural progenitor cells were obtained as previously described36. Mycoplasma testing was 
routinely performed and all cell lines were negative.
cDNA synthesis and RT-PCR
cDNA synthesis was performed with Superscript III First-Strand cDNA synthesis system for 
RT-PCR (Life Technologies) and used for RT-PCR or cloning. qRT-PCR for intron-
containing tRNAs were performed in triplicate on 10 ng human cDNA37. RT-PCR to assess 
toe1 intron inclusion in toe1 Splice blocking morphant zebrafish embryos was assessed with 
10 ng zebrafish cDNA and primers flanking the first intron of zebrafish toe1 (Supplementary 
Table 4).
Plasmid constructs and stable cell line generation
The open reading frame of human TOE1 was subcloned into pcDNA5/FRT/TO-FLAG with 
BamHI and NotI restriction sites from pcDNA3-FLAG38. The open reading frame of 
zebrafish toe1 or human TOE1 was subcloned into pCS2+39 with BamHI and XhoI. 
Missense mutations were generated using the QuickChange Mutagenesis Kit (Agilent). For 
expression of N-terminal FLAG-tagged proteins, stable HEK FLp-In T-REx-293 cell lines 
were generated (Invitrogen). Mycoplasma testing was routinely performed and all cell lines 
were negative.
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Northern blotting
RNA was extracted using Trizol and separated by electrophoresis on 9% 19:1 
polyacrylamide, 0.6× TBE, 8M Urea at 20 mA/gel for 2 hrs. Gels were transferred in 0.5× 
TBE to nylon membrane at 25V for 16 hours. Membranes were UV crosslinked, blocked 
with Ultrahyb Oligo (Life Technologies), and hybridized with 5’ end-radiolabeled DNA 
oligos (see Supplemental Table 4).
3’ RNA tail sequencing and analysis
RNA adapters containing bar-codes and 10–11 nucleotide randomers (see Supplemental 
Table 4) were ligated to the 3’ ends of total and eluted RNA with T4 RNA ligase (NEB) at 
16°C for 16 hr, treated with RQ1 RNase-free DNase (Promega) for 30 min at 37°C and 
extracted with PCA (Affymetrix). cDNA was generated using AR-17 primer with 
Superscript III (Life Technologies). 3’ ends were amplified by Q5 DNA Polymerase (NEB) 
with snRNA gene-specific primers and AR-17, and then with primers D501 and D702 
(Illumina; see Supplemental Table 5). For tRNA 3’ end sequencing, tRNAs were gel purified 
from a 9% polyacrylamide urea gel and libraries were prepared by the eCLIP input RNA 
protocol (Days 3 and 4)40 with AG10N and AG11N 3’ RNA adapters and 3Tr3 5’ DNA 
adapter (Supplementary Table 5). All libraries were purified on AMPure XP magnetic beads 
(Beckman), and validated by 2200 Tape Station (Agilent). Libraries were pooled at 4 nM, 
denatured with NaOH and diluted in HT1 buffer (Illumina) to 7 pM then sequenced with 
MiSeq Reagent Kit V2 Nano configuration (Illumina). snRNA 3’ sequence reads were 
decomplexed, and duplicates removed based on randomer sequences. Sequences were 
aligned with snRNA genes (including downstream regions) from Ensembl. snRNA 3’ end 
positions were identified based on perfect alignment with one or more snRNA genes (reads 
with nucleotide mismatches were removed from the analyses) and 3’ untemplated tails were 
identified as 3’ sequence additions that did not align with the genomic sequence. Each 
experiment generally generated 5,000–35,000 unique mapped reads with the lowest being 
1,173 (Supplemental Table 4). Cumulative plots were generated from reads mapping to all 
U1, U4, U5, and U6 variants, whereas for U2, separate cumulative plots were generated for 
reads mapping to RNU2-1 and RNU2-2P genes, and reads were trimmed for the A and CA 
tails that are post-transcriptionally added to mature RNU2-1 and RNU2-2P RNAs, 
respectively, to allow discrimination of the mature U2 snRNAs from those that are 
incompletely 3’ end exonucleolytically processed (Fig. 4, Fig. 6 and Supplementary Fig. 8b 
and 11a).
RNA Immunoprecipitation and TOE1 activity assay
One 10 cm dish of stable cell lines expressing siRNA-resistant FLAG-TOE1 variants was 
transfected twice with 20 nM siRNA (Dharmacon) targeting either luciferase (siCtrl) or the 
3’UTR of TOE1 (siTOE1) using siLentFect (Bio-Rad) 72 hrs and 24 hrs before harvest. 
Treatment with siTOE1 generally resulted in ~10–20% remaining protein, as determined by 
western blot (Supplementary Fig. 3d). At ~50% density, cells were induced for 24 hrs with 
tetracycline (1 ng/ml), harvested in PBS and lysed in isotonic buffer containing 50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.2 mM EDTA, 0.1% Triton X-100, 1 mM PMSF, 2 µg/mL 
aprotinin, 2 µg/mL leupeptin, 0.1 µg/ml yeast total RNA (Roche), 80 U/mL RNaseOUT 
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(Invitrogen) for 10 minutes on ice. Lysates were cleared at 20K×g for 15 min at 4°C. FLAG 
peptide was added to 1 µg/ml and lysates were incubated for 2 hrs with Anti-FLAG M2 
beads (Sigma) at 4°C, washed 8 times with NET2 (10 mM Tris, pH 7.5, 150 mM NaCl, 
0.1% Triton X-100). One-fifth of the beads were eluted in protein loading buffer, and the rest 
was resuspended in Trizol (Life Technologies). RNA was extracted according to 
manufacturer’s protocol. Activity assays were performed post-wash on-bead for 30 minutes 
at 25°C with either 2 mM EDTA or 2 mM MgCl2.
Western blot
Western blots were performed with rabbit polyclonal anti-Caf1z/Toe14, rabbit polyclonal 
anti-GAPDH (Cell Signaling, 2118s), and mouse anti-Vinculin (Sigma, V9264) at 1:1000 in 
5% non-fat milk in PBST. Secondary antibodies used were HRP anti-mouse and HRP anti-
rabbit at 1:20,000 in 5% non-fat milk in PBST.
Animals
All animal experiments complied with Institutional Animal Care and Use Committee and 
occurred in a non-blinded fashion. The Toe1 mutant mice were generated using CRISPR/
SpCas9 technology. Briefly, pronuclear co-injection of 5 ng Cas9 mRNA and 2.5 ng sgRNA 
(targeting sequence: 5’-CTG TGT GAG ATG TTC CCA GC - 3’) was performed on 143 
embryos. 126 embryos were transferred into host dams for implantation resulting in 23 live 
pups. Sanger sequence genotyping identified only one mouse with a heterozygous single 
base pair frame-shifting mutation, (chr4:116806688-89insA; c.668_669insA), resulting in a 
Toe1 null allele. Adult male and female zebrafish (<18 months old) from wild type (AB 
Tubingen) and transgenic strains were maintained under standard laboratory conditions. At 
least three adult pairs were used to generate embryos at 0–48 hours postfertilization (hpf) for 
each experiment. Translation-blocking antisense morpholino (MO) oligonucleotide (7 ng), 
Splice-blocking antisense MO oligonucleotide (6 ng), and Control non-targeting MO 
oligonucleotide (7 ng) (see Supplementary Table 5) (Gene Tools) were injected into one-cell 
stage embryos. Gross morphology of zebrafish was assessed at 48 hpf, and embryos were 
defined as affected if they had an obviously misshapen head, small eyes, and curly tail 
(>10% reduced head/eye size and >10° angle of tail). HuC/HuD wholemount 
immunostaining was used to assess the presence of neuronal tissue. For mRNA rescue 
experiments, 0.1 pg of in vitro transcribed zebrafish toe1 or human TOE1 mRNA 
(mMESSAGE mMACHINE, Ambion) was co-injected with 6 ng Splice-blocking MO into 
one-cell stage embryos, and assessed at 48 hpf for morphological differences and neuronal 
tissue (minimum of 100 embryos per condition). Immunofluorescent staining was performed 
as previously described41 with rabbit polyclonal caspase-3 primary antibody (Abcam, 
ab13847) and with anti-HuC/HuD mouse monoclonal antibody primary (Thermo Fisher, 
A-21271) and Alexa 488 anti-rabbit or anti-mouse secondary antibody. Zebrafish were 
immobilized in agarose, and fluorescent images were acquired with a Zeiss LSM 780 and an 
Olympus FV1000 confocal microscope. Cells were counted using ImageJ.
Immunocytochemistry
Cells were seeded on coverslips and fixed in 4% PFA or 100% cold methanol, permeabilized 
with 0.1% Triton-X, and blocked with 0.1% BSA, 0.5% gelatin from cold water fish skin in 
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PBS. Cells were incubated with primary antibody in blocking solution overnight at 4°C, 
washed and incubated with secondary antibody in blocking solution and 0.4 µg Hoechst for 
1 hour at room temperature. Primary antibodies used were mouse anti-Nestin (EMD 
Millipore, MAB5326) and rabbit anti-Pax6 (Covance, PRB-278P) at 1:1000. Secondary 
antibodies were Alexa 555 anti-rabbit and Alexa 488 anti-mouse at 1:500. Images were 
taken with an Olympus IX51 inverted fluorescent microscope.
Mass spectrometry
Liquid chromatography mass spectrometry (LC/MS-MS) assays were performed as 
described previously42 from anti-FLAG IP samples from extracts of 293-T-REx cell lines 
stably expressing FLAG-tagged TOE1 WT or TOE1 DE at near endogenous TOE1 levels, 
with a parental cell line serving as a control.
Protein modeling
Needleman-Wunsch alignment of human TOE1 and CNOT7 was performed with protein-
protein BLAST (pBLAST). Homologous TOE1 missense mutations, and previously 
published inactivating mutations (6), were modeled onto the predicted protein structures of 
human CNOT7 (PDB:2D5R) and TOE1 Zinc Finger Domain (PDB:2FC6). Patient 
mutations predicted to result in truncated proteins (e.g. nonsense, splice, and frameshift 
mutations) were excluded from analysis. Residues not in alignment were excluded (F148). 
PyMOL was used to create 3D renderings.
Statistics
Student’s two-tailed paired t-test was employed to test the significance of accumulation of 
extended snRNAs as indicated (Figure 4b and Supplementary Figure 8a) (U1 snRNA: siCtrl, 
siTOE1 p = 0.0054; WT, DE p = 0.0030; WT, RIP WT p = 0.00069; DE, RIP DE p = 
0.0050; U2 snRNA: siCtrl, siTOE1 p = 0.014; WT, DE p = 0.014; WT, RIP WT p = 0.0058; 
DE, RIP DE p = 0.012; U5 snRNA: siCtrl, siTOE1 p = 0.032; WT, DE p = 0.014; WT, RIP 
WT p = 0.011; DE, RIP DE p = 0.0027; U4 snRNA: siCtrl, siTOE1 p = 0.033; WT, DE p = 
0.016; WT, RIP WT p = 0.12; DE, RIP DE p = 0.042; U6 snRNA: siCtrl, siTOE1 p = 0.57; 
WT, DE p = 0.015; WT, RIP WT p = 0.021; DE, RIP DE p = 0.19). Student’s two-tailed 
unpaired t-test was employed to test the significance of Cleaved Caspase 3 positive cells in 
Supplementary Figure 5c (Control MO, toe1 ATG MO p = 0.015)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
TOE1 mutations lead to pontocerebellar hypoplasia with abnormal genitalia (PCH type 7). 
(a) Pedigrees of affected families showing recessive inheritance. Double bar, 
consanguineous marriage; open circle, unaffected female; open square, male; filled circle, 
affected female, filled square, affected male; triangle, spontaneous abortion; open diamond, 
unaffected unknown sex; diagonal line, deceased; arrow, proband. (b) Magnetic resonance 
midline sagittal (top) and axial (bottom) images showing reduced cerebellar volume (yellow 
arrows).
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Figure 2. 
TOE1 mutations occur in conserved domains and amino acid residues and reduce protein 
levels. (a) TOE1 is a 510 amino acid protein containing a DEDD deadenylase domain (red), 
C3H-type Zinc finger (orange), and a nuclear localization signal (NLS, blue). Identified 
homozygous mutations (bold) above, compound heterozygous mutations below, with 
corresponding family number. (b) TOE1 missense mutations showing vertebrate 
conservation. (c) TOE1 mutations (blue) modeled onto solved structures of paralog CNOT7 
and Zn Finger C3H domain of TOE1 (both teal). Residues affecting deadenylase activity 
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(D64, E66; red) occur in the RNA cleft (grey arrow), while the patient mutations are located 
on the protein surface. (d) Western blots (cropped) showing reduced expression of TOE1 in 
affected (A) compared with related unaffected (U) fibroblasts. Control: ATCC fibroblast cell 
line. GAPDH loading control. See Supplementary Fig. 3b for full length blots (e) Impaired 
accumulation of TOE1 protein in affected (A) compared with related unaffected (U) patient-
derived neural progenitor cell (NPC) lines. GAPDH loading control.
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Figure 3. 
Toe1 depletion in zebrafish results in structural brain defects, mimicking human PCH7 
pathology. (a) Comparison of zebrafish at 48 hours post fertilization (hpf) injected with 6 ng 
Control, toe1 ATG morpholino (MO), toe1 Splice-blocking MO, or toe1 Splice-blocking 
MO together with 0.1 pg zebrafish (z) or human (h) TOE1 mRNAs. MO injected fish show 
abnormal head shape and thin, curved tails, which is rescued by addition of zebrafish or 
human WT, but not DE mutant TOE1 mRNA. Scale bar = 500 µm. Quantification at bottom 
right. Normal: no observable phenotype; Moderate: small eyes, slight reduction in head size; 
Severe: small eyes, small head, thin curved tail. n=100/condition. (b) Maximum confocal 
projection of whole mount pan-neuronal HuC immunofluorescence at 48 hpf. Diagram of 
zebrafish anatomy (right). Midbrain, cerebellum, and hindbrain regions of toe1 MO injected 
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zebrafish have reduced HuC protein levels, which were restored with WT zebrafish and 
human TOE1, but not human DE mutant mRNA. Scale bar = 100 µm. n = 6.
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Figure 4. 
TOE1 targets 3’ extended pre-snRNAs. (a) Northern (top) and Western (middle and bottom - 
cropped) blots for cells treated with control (siCtrl) or TOE1 siRNA (siTOE1), then induced 
to express either WT or DE FLAG-TOE1 at near endogenous levels. Input samples (left). 
Samples from RNA immunoprecipitation with anti-FLAG (right). Arrows mark slower 
migrating snRNA species associated with TOE1 DE suggesting impaired processing. (b) 
Left: Cumulative plots of sequence reads for snRNA 3’ ends from the average of 3 
independent experiments. Position ‘0’ refers to mature 3’ end of snRNAs33 with shaded 
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areas indicating 3’ end positions within the mature snRNAs. Reads terminating at position -4 
or after are represented (see Supplementary Figure 8b for all reads). Dotted curves represent 
3’ end positions of genome templated snRNA sequences. Solid curves mark 3’ end positions 
of snRNA sequences, including untemplated tails. Right: Bar graphs showing the average 
percent of snRNA reads with 3’ tails from 3 independent experiments. Independent 
experiments represented by dots. Error bars: standard deviation (S.D.) from three 
independent experiments and p-values (Student’s two-tailed paired t-test) *: p<0.05, **: 
p<0.01. Cumulative plots and bar graphs for U1 and U5 snRNAs represent reads from all 
snRNA variants, whereas for U2 snRNA, reads are from RNU2-1 genes only (see 
Supplementary Figure 8b for RNU2-2P genes) and the 3’ adenosine added to mature 
RNU2-1 snRNAs was left out of the analysis to allow visualization of exonucleolytic 
processing. (c) Schematic of U1 snRNA processing intermediate with 3’ end templated tails 
(encoded nucleotides, pink) and untemplated tails (unencoded nucleotides, purple).
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Figure 5. 
TOE1 enzymatic activity processes snRNA 3’ ends. (a) Northern blot for RNA from TOE1 
activity assays. Left: input samples from RNA of cells treated with siCtrl or siTOE1, then 
induced to express either FLAG-TOE1-WT or -DE at near endogenous levels. Right: 
samples from RIP with anti-FLAG were divided and treated either with 2mM Mg2+ or 2mM 
EDTA on-bead, post-IP; asterisks mark TOE1-processed snRNA. (b) Cumulative plots of 
sequence reads for U1 and U5 snRNA 3’ end positions after incubation with TOE1-WT or -
DE. Dark shaded area indicates reads terminating within the mature U5 snRNA and before 
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the alternative 3’ end (Alt 3’ end). (c) Primary Pol-II transcribed snRNAs (pri-snRNAs) are 
co-transcriptionally cleaved by the Integrator complex. Remaining 3’ tails are subsequently 
processed to mature length by TOE1, in a process that might involve a 3’ terminal 
nucleotidyltransferase (3’ TnT).
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Figure 6. 
Patient-derived fibroblasts and neuronal progenitor cells (NPCs) show defects in snRNA 3’ 
ends. (a) Cumulative U1 and U2 snRNA 3’ end sequence reads from affected (A) and 
unaffected (U) patient fibroblasts, showing TOE1 mutations result in snRNA tails (top). Bar 
graph showing percent reads with 3’ tails (bottom). (b) Cumulative U1 and U2 snRNA 3’ 
end sequence reads from affected and unaffected patient-derived neuronal progenitor (NPC) 
lines showing TOE1 mutations result in snRNA tails for NPCs (top). Percent reads with 3’ 
end tails (bottom).
Lardelli et al. Page 23
Nat Genet. Author manuscript; available in PMC 2017 July 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
